期刊文献+

肝细胞癌手术后应用不同分期评估预后的临床研究 被引量:1

Evaluation of the different staging systems as a predictor of prognosis for hepatocellular carcinoma patients after hepatic resection
原文传递
导出
摘要 目的评估不同肝细胞癌(hepatocellular carcinoma,HCC)分期对HCC肝切除术后的预后判断能力。方法1991年1月至2002年6月西南医院实施根治性肝切除,且具有完整随访资料和临床资料的234例HCC,TNM分期(第6版)与Okuda分期、意大利肝癌工作组(CLIP)评分系统以及香港中文大学预后指数(CUPI)进行比较,利用病例构成比、生存曲线、受试者工作特征曲线(ROC曲线)下面积分别比较各预后评估系统的病例分层能力、术后长时间预后判断能力和预后结果判别能力。结果病例构成比:TNM分期Ⅰ、Ⅱ、Ⅲ期分别为31.6%、29.5%和38.9%;OkudaⅠ、Ⅱ期分别为82.9%和17.1%;CLIP评分系统0、1、2和3分以上分别为37.2%、48.3%、12.4%和2.2%;CUPIⅠ、Ⅱ、Ⅲ级分别为78.6%、20.1%和1.3%。生存率曲线比较:TNM分期Ⅰ期在术后60个月,仍具有明显的预后判断能力,Ⅱ期和Ⅲ期在术后60个月预后接近;Okuda分期和CLIP评分系统术后60个月生存曲线接近;CUPIⅠ级和Ⅱ级在术后60个月后仍然具有良好的预后判断能力。ROC曲线面积比较:TNM分期、Okuda分期、CLIP和CUPI ROC曲线下面积分别为0.683、0.595、0.620和0.596,TNM分期和CLIP评分系统比较存在显著性差异(P=0.0384),CLIP评分系统与CUPI、Okuda分期比较差异无统计学意义(P=0.4681和P=0.3859)。结论对于根治性HCC病例,第6版TNM分期较Okuda分期、CLIP评分系统及CUPI更具有预后判断价值。 Objective To evaluate the 6th edition of TNM staging system for hepatocellular carcinoma in 234 patients after hepatic resection. Methods A retrospective study was carried out in 234 patients after hepatic resection during a period from January 1991 to June 2002. We evaluate the prognostic value of the 6th edition of TNM staging, Okuda staging system, Cancer of the Liver Italian Program (CLIP) scoring system, and Chinese University Prognostic Index (CUPI). The distribution, survival curve and area under a receiver operating characteristic ( ROC ) curve for each stage and substages were used to compare survival rates observed in our patients with surgical operation-related factors. Results Based on TNM staging, 31.6% patients were on Stage Ⅰ disease, 29. 5% patients on Stage Ⅱ disease, and 38.9% patients on Stage Ⅲ disease; Based on Okuda staging, 82.9% on Stage Ⅰ disease, and 17. 1% on Stage Ⅱ disease; By CLIP scoring system, 37. 2% ,48.3%, 12.4% and 2.2% on score 0, 1,2 and 3-4, respectively; By CUPI, 78. 6% , 20. 1% and 1.3% for low, intermediate and high risk group, respectively. The Kaplan-Meier survival curve showed that TNM staging (especially for Stage Ⅰ ) and CUPI could predict long-term survival (60-month) effectively, however, Okuda staging and CLIP scoring lost their prognostic value at 60-month after hepatic resection. The area under the curve (AUC) of TNM, Okuda, CLIP and CUPI was 0. 683, 0. 595, 0. 620 and 0. 596, respectively, as a predictor of clinical outcome at 26. 35-month (median survival time ). Condusion The 6th edition of TNM staging has more significant prognostic value than Okuda staging system, CLIP scoring system and CUPI in HCC patients undergoing hepatic resection.
出处 《中华普通外科杂志》 CSCD 北大核心 2007年第7期514-517,共4页 Chinese Journal of General Surgery
关键词 肝细胞 预后 肿瘤分期 Carcinom, hepatocellular Prognosis Neoplasm staging
  • 相关文献

参考文献8

  • 1Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol, 2002, 20: 1527- 1536.
  • 2Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet, 2003, 361 : 923-929.
  • 3Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer, 2002, 94: 1760-1769.
  • 4Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment, Study of 850 patients. Cancer, 1985, 56: 918-928.
  • 5The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma : a retrospective study of 435 patients. Hepatology, 1998,28 : 751- 755.
  • 6Hanley JA, McNeil BJ. A method of comparing the areas under receive operating characteristic curves derived from the same cases. Radiology, 1983, 148: 839-843.
  • 7Vauthey JN. Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest? J Hepatol, 2003, 38 : 237-239.
  • 8Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusion of the Barcellona-2000 EASL Conference. J Hepatol, 2001, 35: 421-430.

同被引文献23

  • 1Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma [J]. J Gastroenterol Hepatol,2010,25(9):1485.
  • 2Cazals-Hatem D,Rebouissou S,Bioulac-Sage P,et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas [J]. J Hepatol,2004,41(2):292-298.
  • 3Koh KC,Lee H,Choi MS,et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma[J]. Am J Surg,2005,189(1):120-125.
  • 4Tang D,Nagano H,Nakamura M,et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma:a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma[J]. J Gastrointest Surg,2006,10(7):987-998.
  • 5Portolani N,Baiocchi GL,Coniglio A,et al. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma:a Western experience[J]. Ann Surg Oncol,2008,15(7):1880-1890.
  • 6Park SE,Lee SH,Yang JD,et al. Clinicopathological characteristics and prognostic factors in combined hepatocellular carcinoma and cholangiocarcinoma[J]. Korean J Hepatobiliary Pancreat Surg,2013,17(4):152-156.
  • 7Okuda K,Ohtsuki T,Obata H,et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients[J]. Cancer,1985,56(4):918-928.
  • 8Kudo M,Chung H,Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score):its value and limitations,and a proposal for a new staging system,the Japan Integrated Staging Score (JIS score)[J]. J Gastroenterol,2003,38(3):207-215.
  • 9Marrero JA,Fontana RJ,Barrat A,et al. Prognosis of hepa-tocellular carcinoma:comparison of 7 staging systems in an American cohort[J]. Hepatology,2005,41(4):707-716.
  • 10Llovet JM,Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score:a new prognostic system for patients with cirrhosis and hepatocellular carcinoma[J]. Hepatology,2000,32(3):679-680.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部